ABBV AbbVie Inc.

76.46
+1.32  (+2%)
Previous Close 75.14
Open 75.24
Price To Book -13.21
Market Cap 113,044,874,253
Shares 1,478,483,838
Volume 9,480,328
Short Ratio 7.32
Av. Daily Volume 7,938,552
Stock charts supplied by TradingView

NewsSee all news

  1. AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress

    NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™

  2. AbbVie to Host Third-Quarter 2019 Earnings Conference Call

    NORTH CHICAGO, Ill., Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market

  3. Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction

    DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

  4. AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

    NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE:AGN) have each received a Request

  5. AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

    NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Depatuxizumab mafodotin ABT-414
Glioblastoma (rGBM)
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017.
ABBV-8E12
Alzheimer's disease
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due in 2021.
Venetoclax - CANOVA
Relapsed or refractory multiple myeloma
FDA approval announced April 23, 2019.
Risankizumab
Psoriasis
Approval announced August 2, 2017.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Phase 3 trial to commenced 2017.
ABT-494
Psoriatic Arthritis
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2b data released September 7, 2017 - primary endpoint met. Phase 3 trial to be initiated 1H 2018.
ABT-494
Atopic Dermatitis
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
NDA filing announced August 5, 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
FDA Approval announced August 16, 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Rova-T (MERU)
First-line Small Cell Lung Cancer
FDA approval announced January 28, 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
Phase 3 primary endpoint not met (PFS/OS).
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2H 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
sNDA filing announced June 4, 2019.
Venetoclax and obinutuzumab
Chronic lymphocytic leukemia
Phase 3 presentation at ESMO 28 September 2019.
Veliparib
Ovarian cancer
Phase 3 data presented at EADV October 10, 2019.
Risankizumab ( LIMMITLESS )
Psoriasis

Latest News

  1. AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress

    NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™

  2. AbbVie to Host Third-Quarter 2019 Earnings Conference Call

    NORTH CHICAGO, Ill., Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market

  3. Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction

    DUBLIN, Sept. 27, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS

  4. AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

    NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE:AGN) have each received a Request

  5. AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

    NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval

  6. VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada

    MONTREAL, Sept. 25, 2019 /CNW/ - AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced today that Alberta, Manitoba, British Columbia and Saskatchewan are listing VENCLEXTA®

  7. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  8. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  9. AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®

    NORTH CHICAGO, Ill., Sept. 23, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present results from two late-breaking

  10. Thinking about buying stock in AbbVie, Aurora Cannabis, Catalyst Pharmaceuticals, Fibrocell Science, or MER Telemanagement Solutions?

    NEW YORK, Sept. 13, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, ACB, CPRX, FCSC, and MTSL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  11. Advances in Biotechnology May Offer Cancer Patients Renewed Hope

    NEW YORK, Sept. 10, 2019 /PRNewswire/ -- The biotechnology market is currently one of the largest industries in the world. Biotechnology is defined as technology that is used to modify or upgrade the biological system,

  12. AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Sept. 6, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) declared a quarterly cash dividend of $1.07 per share.  The cash dividend is payable November 15, 2019 to stockholders

  13. AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program

    NORTH CHICAGO, Ill., Aug. 29, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy

  14. AbbVie to Present at the Morgan Stanley Healthcare Conference

    NORTH CHICAGO, Ill., Aug. 27, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday,